TABLE 1.
Demographics and clinical features across six PSP groups
| Variable | PSP‐RS, N = 48 | PSP‐P, N = 20 | PSP‐PGF, N = 8 | PSP‐SL, N = 8 | PSP‐CBS, N = 7 | PSP‐Other, N = 6 | P |
|---|---|---|---|---|---|---|---|
| Female, n (%) | 22 (46%) | 6 (30%) | 6 (75%) | 4 (50%) | 3 (43%) | 5 (83%) | 0.16 |
| Age at Encounter | 70.3 (65.2, 74.8) | 70.4 (68.0, 74.0) | 74.4 (71.9, 77.6) | 73.9 (70.0, 77.1) | 69.7 (64.2, 71.5) | 68.5 (57.9, 75.6) | 0.10 |
| Age at onset | 65.7 (61.8, 70.0) | 64.8 (58.7, 68.0) | 71.5 (67.7, 76.2) | 67.3 (62.4, 69.3) | 68.0 (62.4, 69.4) | 64.1 (52.2, 72.5) | 0.14 |
| R‐Hand, n (%) | 40 (85%) | 16 (89%) | 5 (71%) | 8 (100%) | 6 (86%) | 5 (83%) | 0.72 |
| Education, y | 16 (14, 16) | 16 (14, 16) | 15 (14, 16) | 16 (15, 18) | 12 (12, 15) | 12 (12, 16) | 0.31 |
| On antidepressant at study entry, n (%)** | 29 (60%) | 12 (60%) | 4 (50%) | 6 (75%) | 5 (71%) | 5 (83%) | 0.82 |
| PSP Rating Scale | 37.5 (30.8, 46.0) | 39.0 (34.5, 42.8) | 32.0 (30.2, 38.8) | 42.0 (37.8, 50.2) | 34.0 (20.5, 51.0) | 28.0 (24.8, 31.2) | 0.58 |
| MoCA | 24 (21, 27) | 26 (23, 27) | 26 (24, 26) | 22 (18, 24) | 21 (17, 24) | 24 (22, 25) | 0.22 |
| FAB | 14 (13, 16) | 14 (13, 16) | 15 (13, 16) | 12 (10, 13) | 12 (8, 14) | 12 (10, 14) | 0.03 |
| Boston naming | 14 (12, 14) | 14 (12, 15) | 12 (12, 13) | 15 (15, 15) | 11 (10, 12) | 13 (12, 14) | 0.10 |
| ASRS | 4 (2, 6) | 4 (2, 6) | 2 (1, 3) | 33 (26, 44) | 3 (2, 5) | 4 (3, 6) | <0.001 |
| Disease Duration at encounter | 3.36 (2.33, 4.33) | 5.40 (4.49, 10.01) | 3.08 (2.37, 3.35) | 7.63 (5.85, 8.95) | 2.34 (1.88, 2.71) | 3.87 (2.30, 6.45) | <0.001* |
| GDS total | 5.5 (3.8, 7.2) | 4.5 (3.0, 6.2) | 6.0 (5.0, 8.2) | 2.5 (1.8, 3.2) | 4.0 (3.0, 5.5) | 7.0 (5.5, 7.0) | 0.07 |
| AES total | 19.0 (10.8, 29.2) | 24.0 (14.5, 32.8) | 12.5 (7.5, 23.0) | 10.0 (7.5, 24.5) | 17.0 (8.0, 24.0) | 18.0 (16.0, 20.0) | 0.44 |
| GDS ≥5 (%) | 28 (58%) | 10 (50%) | 6 (75%) | 1 (12%) | 3 (43%) | 6 (100%) | 0.02* |
| AES ≥36 (%) | 7 (15%) | 3 (15%) | 1 (12%) | 0 (0%) | 0 (0%) | 1 (17%) | 0.90 |
| Disease duration | GDS total score | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PSP‐P | PSP‐PGF | PSP‐SL | PSP‐CBS | PSP‐Other | PSP‐P | PSP‐PGF | PSP‐SL | PSP‐CBS | PSP‐Other | ||
| PSP‐RS | <0.001 | >0.99 | 0.001 | 0.77 | 0.93 | PSP‐RS | 0.60 | 0.46 | 0.02 | 0.69 | 0.07 |
| PSP‐P | NA | 0.04 | 0.94 | 0.002 | 0.58 | PSP‐P | NA | 0.40 | 0.10 | >0.99 | 0.053 |
| PSP‐SL | NA | 0.02 | NA | 0.001 | 0.28 | PSP‐SL | NA | 0.04 | NA | 0.28 | 0.005 |
| PSP‐PGF | NA | NA | NA | 0.98 | 0.91 | PSP‐PGF | NA | NA | NA | 0.31 | 0.47 |
| PSP‐CBS | NA | NA | NA | NA | 0.53 | PSP‐CBS | NA | NA | NA | NA | 0.07 |
The PSP‐Other group consisted of PSP‐PI, PSP‐OM, and PSP‐F. Data shown as n (%) or median (IQR).
*
Pairwise P‐values.
**
Sertraline (23%), citalopram (13%), escitalopram (13%), trazodone (11%), mirtazapine (10%), bupropion (8%), duloxetine (8%), paroxetine (5%), venlafaxine (5%), fluoxetine (3%), desvenlafaxine (2%), antidepressant name unknown (3%). Some patients were on more than one antidepressant.
Abbreviations: AES, Apathy Evaluation Scale; ASRS, Apraxia of Speech Rating Scale; FAB, Frontal Assessment Battery; GDS, Geriatric Depression Scale.